Pelvic organ prolapse affects numerous women globally, causing discomfort and emotional distress that can disrupt daily activities. Despite its prevalence, many cases remain unreported due to stigma. Sylvia Health, a Danish startup, is working on a medical device designed to help women experiencing this issue. This approach by Sylvia Health points to significant attention and innovation in women’s health.
Reportedly, pelvic organ prolapse affects over 200 million women worldwide. Sylvia Health’s ongoing efforts aim to improve the lives of those affected. Previously, the issue of pelvic prolapse and the problems with transvaginal mesh received little attention despite worldwide legal battles and countless affected lives. However, Sylvia Health emphasizes developing solutions focusing directly on anatomical needs, contrasting with past approaches where the focus had often been on general solutions.
What Has Sylvia Health Achieved So Far?
Sylvia Health emerged from the Novo Nordisk Foundation BioMedical Design Fellowship Programme, based on several months of clinical observations. The company focuses on innovating medical devices suited to the anatomical needs of women with certain types of prolapse. The initial prototypes, tested with the help of women living with prolapse, aimed to be both practical and user-friendly. In 2023, following the program’s conclusion, Sylvia Health developed its first medical-grade prototypes.
The startup’s research and development team incorporates feedback from gynaecologists and women affected by the condition. Collaboration with pelvic health physiotherapists has further underscored the potential of these prototypes and refined them for better clinical outcomes. This showcases Sylvia Health’s commitment to a user-centred design approach.
How Could Sylvia Health’s Device Affect the Industry?
Transvaginal mesh has been a common treatment for pelvic organ prolapse, but it has been under scrutiny due to adverse effects reported by many women. The lack of innovation in the area of prolapse treatment, as seen by Sylvia Health, presents an opportunity for better solutions. Their device, akin to modified menstrual cups functionally supporting prolapse instead of collecting fluid, could potentially offer a less invasive option that aligns more closely with the body’s requirements.
Current solutions, like surgery and pessaries, have limitations for many women. Sylvia Health’s patent-pending device aims to fill the gap by offering increased efficacy with minimal invasiveness. Stretton believes their focus on patient-centric design positions the device as a prospective prescribed medical device. They aim for widespread distribution, starting in Denmark and possibly expanding to larger European markets, pending the proof of concept and business viability.
Finally, the Sylvia Health team is focused on evaluating safety and quality-of-life impacts through clinical trials. With future steps surrounding commercialisation and possibly collaborating with strategic partners, Sylvia Health looks to amplify its reach substantially.
Ongoing clinical trials target to measure changes in quality of life for women using the device, alongside efforts towards obtaining regulatory approval based on an acceptable safety profile.
As Sylvia Health advances this innovative project, addressing pelvic organ prolapse from an anatomy-first perspective signals a fresh direction. This approach could significantly impact future treatment modalities and offer an alternative solution for millions of women. The company is actively seeking partnerships for potential global distribution following successful initial market entry.
